DexCom: Revenue Up, EPS Misses Mark
(NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue, which reached $1.114 billion, slightly exceeding analysts' expectations of $1.112 billion. However, the company's Non-GAAP earnings per share (EPS) were $0.45, which fell short of the forecasted $0.50. The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating incomes. Despite these mixed results, DexCom's revenue trajectory indicates ongoing expansion, especially in international markets.
Source: Analyst estimates for the quarter provided by FactSet.
DexCom specializes in continuous glucose monitoring systems, primarily focusing on individuals managing diabetes. Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose level tracking, giving users actionable insights. The company has been concentrating on product development, aiming to refine and expand its offerings with advances in technology such as artificial intelligence. DexCom’s growth hinges on innovation, regulatory approvals, and broadening its market reach domestically and internationally.
Source Fool.com
Dexcom Inc. Aktie
Die Community bevorzugt klar Dexcom Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Mit einem Kursziel von 75 € für Dexcom Inc. könnte eine leichte Steigerung gegenüber dem aktuellen Kurs von 73.4 € erreicht werden.
